1. Introduction {#sec1-jcm-08-02158}
===============

Osteonecrosis of the femoral head (ONFH) commonly affects middle-aged adults and there are more than 10,000 incidental ONFH per year reported in the United States \[[@B1-jcm-08-02158]\]. ONFH is an avascular necrotic process of bone or marrow with mild and ambiguous symptoms in early stage and potentially disabling in late stage \[[@B2-jcm-08-02158],[@B3-jcm-08-02158]\]. With the disease progression, the last effective therapy for advanced ONFH can only be resorted to total hip replacement \[[@B4-jcm-08-02158],[@B5-jcm-08-02158]\]. In fact, ONFH accounts for more than 10% of total hip replacement in the United States \[[@B6-jcm-08-02158]\] where nearby 80% of non-traumatic ONFH may attribute to steroid and alcohol use \[[@B7-jcm-08-02158],[@B8-jcm-08-02158]\]. Especially, the relatively young victims of ONFH often need multiple replacement surgeries in their lifetime \[[@B9-jcm-08-02158]\].

The exact pathogenesis of ONFH remains unidentifiable and is still possible to be identified in the future. The disease mechanisms of ONFH are often considered as multifactorial, including trauma, drug, surgery, and idiopathic causes \[[@B1-jcm-08-02158],[@B10-jcm-08-02158],[@B11-jcm-08-02158]\]. Recently, growing evidence has shown that endothelial dysfunction related inappropriate nitric oxide production may be one of the key causative factors for ONFH \[[@B12-jcm-08-02158],[@B13-jcm-08-02158],[@B14-jcm-08-02158],[@B15-jcm-08-02158],[@B16-jcm-08-02158]\]. Endothelial cell injury or dysfunction is well known as one of the fundamental risk factors for venous thromboembolic events (VTE) \[[@B17-jcm-08-02158]\]. Undoubtedly, surgery, especially of lower extremities, substantially increases the risk of VTE \[[@B18-jcm-08-02158]\]. Hence, anticoagulant or intermittent pneumatic compression for thromboprophylaxis in patients receiving surgery to reduce perioperative thromboembolism is recommended by clinical guidelines \[[@B19-jcm-08-02158]\]. Compared to those with other reasons for lower limb surgery (LLS), ONFH population develops symptoms in young age, possesses diathesis of endothelial dysfunction, and may undergo several times of hip surgery in their lifetime. In a study comparing 20 ONFH patients with age-, gender-, income- and urbanization-matched population, the incidence and risk of unprovoked VTE are significantly higher in ONFH patients. However, subjects who had LLS within one year since enrollment or diagnosed with VTE within one year after surgery were excluded in that study \[[@B20-jcm-08-02158]\]. Thus, the risk of postoperative VTE in patients with ONFH undergoing hip replacement surgery remains regrettably unanswered. In this study, we intended to investigate whether the risk of VTE after hip replacement surgery is significantly higher in patients with ONFH than those without ONFH.

2. Materials and Methods {#sec2-jcm-08-02158}
========================

2.1. Data Source from Taiwan National Health Insurance Research Database (NHIRD) {#sec2dot1-jcm-08-02158}
--------------------------------------------------------------------------------

Healthcare is provided to near 99% of the 23.74 million Taiwanese by Taiwan National Health Insurance program \[[@B21-jcm-08-02158]\]. The database collects information from 97% of the hospitals and clinics in Taiwan. The researchers can register and claim data of residents systematically selected from all insured enrollees of the NHIRD. The dataset included robust information regarding medical facilities, details of inpatient and outpatient orders, dental services, regimen prescription, patient care provided by physicians, and other registration files, e.g., payment, regions, and catastrophic illness, except for laboratory data and examination reports. Diagnoses are entered based on the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). This study was approved by the Ethics Institutional Review Board of Chang Gung Memorial Hospital (IRB No. 201900220B0).

2.2. Study Population {#sec2dot2-jcm-08-02158}
---------------------

This was a retrospective nationwide population-based cohort study. From January 1997 to December 2013, 391,688 subjects undergoing LLS (procedure codes: 64162B, 64164B, 64169B, 64170B, 64201B, 64258B) were selected from all insured individuals in Taiwan NHIRD. LLS comprised partial and total replacements of hip or knee and revision operations. A total of 299,321 subjects who had received LLS for the first time were enrolled, because repeated surgeries would significantly increase the risk of VTE and confound the study interpretation. Subsequently, 157,394 eligible subjects undergoing partial or total hip replacement (PHR or THR, codes: 64170B, 64162B) and revision operations (64201B, 64258B) were chosen. We further divided them into the study and control groups according to the diagnosis of ONFH or not (ICD-9-CM codes: 733.42), regardless of traumatic or non-traumatic types. After excluding those with VTE diagnosed before LLS, age \< 18 years old and missing baseline information, the study and control groups were matched by age, sex, income, urbanization and types of surgery in a 1:1 ratio. Finally, a total of 12,232 ONFH and 12,232 non-ONFH patients were enrolled ([Figure 1](#jcm-08-02158-f001){ref-type="fig"}). Additionally, ONFH patients undergoing primary PHR or THR for the contralateral lesion or revision operations for primary PHR or THR failure were also excluded.

Urbanization was categorized into four levels, i.e., from level 1 to 4 corresponding to the least (country) to the most urbanized level (city). Insurance taxable income level was stratified into four classifications based on monthly insurance payment of individual insured enrollee, i.e., level 1: none, level 2, 1--15,840, level 3: 15,841--25,000, and level 4: \>25,000 New Taiwan Dollars per month. These two background parameters were matched between groups to eliminate the baseline differences in patients' lifestyle and socioeconomic status.

2.3. Diagnosis Confirmation and Acquisition of Medical and Surgical Information {#sec2dot3-jcm-08-02158}
-------------------------------------------------------------------------------

Diagnostic data of VTE, including deep venous thrombosis (DVT; ICD-9-CM codes 453.8) and pulmonary embolism (PE; 415.1), were retrieved from NHIRD based upon entered clinical or hospitalization information \[[@B22-jcm-08-02158]\]. The diagnoses were documented by at least three records of consecutive outpatient visits within one year or one proved diagnosis on admission during study period. We also checked the corresponding thrombolytic agents or anticoagulants to confirm these venous thromboembolic diagnoses. Additionally, drug exposure to non-steroidal anti-inflammatory drug (NSAID) or systemic corticosteroid therapy (steroid) was defined as the regimen prescription duration for ≥1 month. In contrast, we defined those without prescription or short-term (\<1 month) use of the above two medications as non-drug exposure, because they might be prescribed for other purposes, rather than standard treatment or symptomatic relief for ONFH.

Data of surgical procedures were retrieved from Taiwan Health Insurance surgical files in which total patients' information of the performed orthopedic surgical procedures were registered. The relevant diagnoses, surgical types, date, and locations were acquired for baseline matching and further analysis. The first day of surgery was defined as surgical index date. Those with missing or incomplete data entered were excluded from the study.

2.4. Comorbidities and Outcomes {#sec2dot4-jcm-08-02158}
-------------------------------

The first day since the patient's enrollment was defined as the index date. During the 17-year dataset period, we evaluated the comorbidities including traditional atherosclerotic risk factors, relevant cardiovascular or non-cardiovascular systemic diseases for each subject followed. Diagnoses of comorbid diseases were confirmed by the same three consecutively ICD-9-CM codes, such as hypertension (ICD-9-CM codes 401-405), diabetes (250), dyslipidemia (272), gout (274), systemic lupus erythematosus (710.0), atrial fibrillation (427.31), chronic ischemic heart disease (412--414, 429.2), peripheral vascular disease (440, 443.9,444.0, 444.2, 444.8, 444.9, 447.8, 447.9, 445.0, 445.02), chronic kidney disease (585), and obesity (278). The frequency of the above comorbidities in these two groups during the whole study period were evaluated and compared.

The first day of clinical events, i.e., VTE, DVT, or PE, was defined as event date and was censored as the end of study. We aimed to evaluate the frequency and incidence of VTE after PHR, THR, or revision operation in both ONFH and non-ONFH groups. Additionally, the risk of VTE after hip surgery for ONFH was analyzed to clarify whether the risk is higher in the ONFH than non-ONFH group. Furthermore, whether the risk changes with duration of drug exposure or time period after surgery was also clarified.

2.5. Statistical Analysis {#sec2dot5-jcm-08-02158}
-------------------------

After matching with age, sex, socioeconomic status, and types of surgery, the demographic data and frequency of comorbidities and outcomes between the ONFH and matched non-ONFH cohorts were compared with the independent t and Chi-square tests as appropriate. The incidence rate and 95% confidence interval (CI) of VTE, including DVT and PE, were calculated between groups in the entire follow-up period. Additionally, we used the Kaplan-Meier method to estimate cumulative incidences in both groups and performed the Log-rank test to examine differences between them. By using Cox proportional hazard regression model, risks of ONFH for VTE, DVT, and PE were analyzed and the data was expressed with the hazard ratio (HR) concomitant with 95% CI for each parameter. Multivariate analysis was adjusted for background parameters including age, sex, urbanization, and income levels, and drug exposure under the circumstance of matched surgical procedures. Two-tailed *p*-value \< 0.05 was considered statistically significant. All analyses were conducted using SAS statistical software (Version 9.4; SAS Institute, Cary, NC, USA).

3. Results {#sec3-jcm-08-02158}
==========

3.1. Demographic Data of the Surgical Patients with and without ONFH {#sec3dot1-jcm-08-02158}
--------------------------------------------------------------------

[Table 1](#jcm-08-02158-t001){ref-type="table"} shows that more than one half of ONFH patients were male and underwent first hip surgery before 65 years old, with the median age about 62 years old. Only a minority of them had a poor socioeconomic status. About 70% and 30% of ONFH cases received THR and PHR, respectively, at the first time of hip surgery. Even though we excluded those with repeated LLS in the beginning, there were still 1% of cases undergoing revision operation, suggesting their first primary THR or PHR was performed before 18 years ago. Additionally, the surgical ONFH patients had significantly higher frequencies of dyslipidemia, gout, and systemic lupus erythematosus (all *p* \< 0.002). By contrast, non-ONFH population had significantly more prevalence of diabetes and obesity (all *p* \< 0.02). Of note, one third of ONFH patients had concomitant coronary heart disease. The frequency of drug exposure to NSAID or steroid for ≥1 month was significantly higher in the ONFH than non-ONFH group (all *p* \< 0.001). More than 80% of ONFH patients still needed long-term use of NSAID for pain relief after surgery.

3.2. Outcome Comparison for Incidence Rate and Adjusted Risk of VTE, DVT, and PE {#sec3dot2-jcm-08-02158}
--------------------------------------------------------------------------------

During the mean follow-up period of 6.4 years, the ONFH patients undergoing hip surgery did not have significantly higher frequencies of VTE, DVT, and PE compared with the non-ONFH group (all *p* = NS) (ref. the bottom of [Table 1](#jcm-08-02158-t001){ref-type="table"}). [Table 2](#jcm-08-02158-t002){ref-type="table"} displays the incidence rate of VTE was 21.2 and 19.4 per 100,000 person-years in the ONFH and non-ONFH group, respectively. Therefore, there was no evidence that the surgical ONFH patients had an increased risk for incidental VTE compared to those without ONFH given the statistical result (95% CI 0.88--1.36; *p* = 0.440). Also, the incidences of DVT and PE displayed the similar insignificant pattern to that of VTE. Regarding occurrence of VTE in relation to time period since first hip surgery for ONFH, the Kaplan-Meier curve in [Figure 2](#jcm-08-02158-f002){ref-type="fig"} demonstrates that there were similar cumulative incidences of VTE, including DVT and PE, among the ONFH and non-ONFH groups in the 17-year study period (all *p* = NS with Log-rank test).

Stratified analysis on [Table 2](#jcm-08-02158-t002){ref-type="table"} demonstrates the risk of VTE in ONFH was essentially invariant with not only the duration of drug exposure to NSAID and steroid, but also the time period after hip surgery, suggesting there was no short-term or long-term concern about increased risk of postoperative VTE in the ONFH population receiving major hip replacement surgery.

3.3. Multivariate Analysis for Identifying the Risk Factors for Post-Operative VTE, DVT and PE {#sec3dot3-jcm-08-02158}
----------------------------------------------------------------------------------------------

As shown in [Table 3](#jcm-08-02158-t003){ref-type="table"}, the results of Cox regression analysis adjusted for age, sex, socioeconomical background, comorbidities, and drugs revealed that advanced age was significantly associated with increased risk of VTE, DVT, and PE. On the contrary, short- or long-term use of NSAID was incidentally found to be protective against VTE. The interesting finding can be attributed to that early/normal ambulation after hip surgery by adequate pain control might be helpful to prevent attack of VTE. Additionally, other underlying diseases, aside from ONFH, were found not to increase the risk of VTE after surgery. Again, steroid use, which was an independent risk factor for ONFH and strongly associated with endothelial dysfunction, also did not increase VTE risk.

4. Discussion {#sec4-jcm-08-02158}
=============

The present study using Taiwan NHIRD to compare the risk of post-operative VTE between ONFH and matched non-ONFH patients yielded several novel findings and provided useful clinical information. Firstly, the incidences of VTE, DVT, and PE were slightly but insignificantly higher in the ONFH than non-ONFH group undergoing the same types of hip surgery. Secondly, the surgical ONFH patients did not have a significantly increased risk of VTE as compared with surgical non-ONFH counterparts. Thirdly, there were no increased risks for VTE in the ONFH subgroups stratified by comorbidities, durations of drug exposure to NSAID or steroid, and follow-up periods after surgery. These findings from an Asian population-based study implied that although ONFH patients have underlying pathological mechanism of endothelial dysfunction, they did not have higher postoperative risk of VTE, including DVT and PE, as compared to those without ONFH. As a result, we suggested hip replacement surgery could be equally safe in the ONFH population without an extra need of increased dose or duration of prophylactic oral anticoagulant in terms of an increased risk for surgery-related VTE.

Two previous clinical observational researches to investigate the association between ONFH and cardiovascular diseases \[[@B14-jcm-08-02158],[@B20-jcm-08-02158]\] have shown positive results that both major adverse cardiovascular or cerebrovascular events (MACCE) and VTE were significantly increased in the ONFH population as compared with the general population. The underlying mechanism is thought to be related to the endothelial dysfunction. In the former study \[[@B14-jcm-08-02158]\], the ONFH patients were found to have about twice increased risk for MACCE even after multivariate adjustment for medications, surgery and relevant comorbidities. The latter study was aimed to find the incidence of unprovoked VTE in non-traumatic ONFH \[[@B20-jcm-08-02158]\]. Those subjects with precedent trauma, underwent LLS in one year, and occurrence of VTE within one year after surgery were excluded, due to an obviously increased VTE risk through blood stasis and vascular/endothelial injury, the two crucial components of Virchow's triad \[[@B23-jcm-08-02158]\]. Notably, nontraumatic ONFH was found to be doubly risky for unprovoked VTE as compared with general population. However, whether ONFH patients, either traumatic or nontraumatic, undergoing major hip replacement surgery would have higher post-operative VTE risk compared to matched control group remains unanswered.

In the previous study, the incidences of unprovoked VTE, DVT, and PE were 1.2%, 1.0%, and 0.2%, respectively \[[@B20-jcm-08-02158]\]. Current study found the corresponding incidences were slightly increased to 1.4%, 1.1%, and 0.4%, respectively. These results are reasonable because the extrinsic pathway of coagulation cascade triggered by surgery may only have marginal effect and plateaued on the risk of VTE when the intrinsic pathway in ONFH patients has already been primed \[[@B24-jcm-08-02158]\]. Nevertheless, while comparing to another data also from Asia showing that asymptomatic thrombophlebitis diagnosed with ultrasound is about 5% \[[@B25-jcm-08-02158]\], we noted that VTE after hip surgery in Taiwan was quite low, i.e., only around 1%, even without anticoagulant prevention. Therefore, we were not sure whether the result could become statistically significant if asymptomatic VTE were detected by ultrasound or other image studies. It is also possible that the incidence of VTE in our study might be underestimated due to the inherent limitations of this administrative database. Furthermore, the rate of VTE in some western populations is around 10% in absence of thromboprophylaxis, and the rate of asymptomatic thrombophlebitis is even up to 20% \[[@B26-jcm-08-02158]\]. Taken together, application of the results from our Asian-based study for non-Asian populations needs careful interpretation and more investigation.

Short-term or long-term administration of NSAID protected ONFH patients from postoperative VTE was noted in the present study. Also, data from the previous two studies \[[@B14-jcm-08-02158],[@B20-jcm-08-02158]\] have documented that NSAID has the protective effects against not only provoked VTE but also MACCE in patients with nontraumatic ONFH. Although most early researches have shown the use of non-selective NSAID strongly leads to endothelial dysfunction and links to arterial/venous thrombotic complications \[[@B27-jcm-08-02158],[@B28-jcm-08-02158]\], yet more and more recent meta-analyses have challenged the cardiovascular safety issue of NSAID, especially cyclooxygenase-2 (COX-2) selective inhibitor \[[@B29-jcm-08-02158],[@B30-jcm-08-02158]\]. Our findings, corresponding to less safety concern about thrombogenic property of NSAID in the recent reviews, supported the use of NSAID transiently or regularly for pain relief of ONFH not only did not increase the both risks of unprovoked VTE and MACCE, but also protected against surgery-related VTE. Adequate pain control was supposed to facilitate early ambulation in those surgical ONFH patients, and then further prevent thromboembolic events.

We did not find an increased postoperative risk of VTE in Asian ONFH population in the present study. The analytical results were consistent after stratified with age, gender, comorbidities, duration of drug exposure and postoperative period. Furthermore, the incidence of VTE in ONFH after surgery was about 1.4% and the risk did not increase within 1 month or even beyond 5 years after surgery. Therefore, based upon the present findings, titration up of anticoagulant dose or extension of anticoagulant duration for enhancement of thromboprophylaxis might be not suggested for Asian ONFH patients who require surgery or have received an operation. At least, we can safely follow standard thromboprophylactic strategies recommended by current guidelines \[[@B19-jcm-08-02158]\].

There were some study limitations. First, detailed personal history and lifestyle information such as smoking, alcohol, body mass index, and life independence are not provided by Taiwan NHIRD. Second, all data have been registered with ICD-9-CM codes, and therefore further classification of disease severity was impracticable. The possibility of misclassification bias might also be considered. Third, the laboratory data and detailed examination reports are not available in NHIRD, so all diagnostic precisions depend solely upon entered data. Fourth, pharmacological or mechanical thromboprophylaxis was not routinely adopted in preoperative setting in Taiwan, and therefore we did not analyze the impact of preoperative anticoagulants on the risk of VTE between groups. Fifth, there was no information regarding over-the-counter medication use. Finally, NHIRD is a nationwide database of Asian population. Although the prevalence and incidence of VTE were compatible with the systematically reviewed data \[[@B31-jcm-08-02158]\], ethnic difference shall be taken into account while applying the study results into clinical practice globally.

5. Conclusions {#sec5-jcm-08-02158}
==============

The risk of VTE, including DVT and PE, after major hip replacement surgery was similar among the Asian patients with and without ONFH. Further research in this area is needed to confirm whether titration up of anticoagulant dose or extension of anticoagulant duration is warranted in this population.
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![Flow diagram regarding how eligible patients were selected and allocated into the ONFH and matched non-ONFH groups. Non-ONFH group undergoing hip surgery was selected by matching ONFH group with age, sex, socioeconomic status, and types of surgery in a 1:1 ratio after excluding repeated surgeries, VTE before LLS, age \< 18 years old, and incomplete or missing detailed information. Abbreviation: NHIRD---National Health Insurance Research Database; LLS---lower limb surgery; ONFH---osteonecrosis of femoral head; VTE---venous thromboembolic events.](jcm-08-02158-g001){#jcm-08-02158-f001}

![Cumulative incidence of (**A**) VTE, (**B**) DVT, and (**C**) PE in the surgical patients with and without ONFH in 17-year dataset period. Abbreviation: VTE---venous thromboembolic events; DVT---deep vein thrombosis; PE---pulmonary embolism; ONFH---osteonecrosis of femoral head.](jcm-08-02158-g002){#jcm-08-02158-f002}

jcm-08-02158-t001_Table 1

###### 

Demographic characteristics and outcome of VTE in the surgical patients with and without ONFH, matched by any type of hip surgery.

  -------------------------------------------------------------------------------------------
                                 ONFH Group\     Non-ONFH \* Group\                 
                                 (*n* = 12232)   (*n* = 12232)                      
  ------------------------------ --------------- -------------------- ------ ------ ---------
  Gender                                                                            1.000

  Female                         5654            46.2                 5654   46.2   

  Male                           6578            53.8                 6578   53.8   

  Age (years)                                                                       1.000

  18--65                         6533            53.4                 6533   53.4   

  \>65                           5699            46.6                 5699   46.6   

  Median age (IQR)               61.9 (53--72)   61.9 (53--72)                      

  Urbanization level                                                                1.000

  1 (rural)                      1212            9.9                  1212   9.9    

  2                              2441            20.0                 2441   20.0   

  3                              5990            49.0                 5990   49.0   

  4 (urban)                      2589            21.2                 2589   21.2   

  Income level                                                                      1.000

  1 (lowest)                     3319            27.1                 3319   27.1   

  2                              2075            17.0                 2075   17.0   

  3                              4896            40.0                 4896   40.0   

  4 (highest)                    1942            15.9                 1942   15.9   

  Surgical procedure                                                                1.000

  THR                            8516            69.6                 8516   69.6   

  PHR                            3596            29.4                 3596   29.4   

  Revision of hip replacement    120             1.0                  120    1.0    

  Comorbidities                                                                     

  Hypertension                   7694            62.9                 7836   64.1   0.059

  Diabetes mellitus              3592            29.4                 3902   31.9   \<0.001

  Dyslipidemia                   4597            37.6                 4350   35.6   0.001

  Gout                           3138            25.7                 2658   21.7   \<0.001

  Systemic lupus erythematosus   214             1.7                  61     0.5    \<0.001

  Atrial fibrillation            649             5.3                  622    5.1    0.437

  Coronary heart disease         3836            31.4                 3734   30.5   0.158

  Peripheral vascular disease    1010            8.3                  1048   8.6    0.381

  Chronic kidney disease         1217            9.9                  1248   10.2   0.510

  Obesity                        116             0.9                  156    1.3    0.015

  Drug exposure (\>1 month)                                                         

  NSAID                          10,242          83.7                 9623   78.7   \<0.001

  Steroid                        4099            32.8                 3255   26.6   \<0.001

  Outcomes                                                                          

  VTE                            167             1.4                  152    1.2    0.398

  DVT                            133             1.1                  115    0.9    0.251

  PE                             44              0.4                  46     0.4    0.833
  -------------------------------------------------------------------------------------------

\* Control group (non-ONFH group) was matched by age, gender, income/urbanization level, and types of hip surgery. Abbreviations: VTE---venous thromboembolic event; ONFH---osteonecrosis of femoral head; No.---number; IQR---interquartile range; THR---total hip replacement; PHR---partial hip replacement; NSAID---non-steroid anti-inflammatory drug; DVT---deep venous thrombosis; PE---pulmonary embolism.

jcm-08-02158-t002_Table 2

###### 

Stratified comparison of incidence rate and risk of VTE between the surgical patients with and without ONFH.

                                   ONFH (*n* = 12232)   Non-ONFH (*n* = 12232)                                                          
  -------------------------------- -------------------- ------------------------ ------- ----- ----------- -------- ------ ------------ -------
  VTE                              167                  78,820.55                21.19   152   78,224.69   19.43    1.09   0.88--1.36   0.440
  DVT                              133                  78,940.20                16.85   115   78,356.04   14.68    1.15   0.89--1.47   0.279
  PE                               44                   79,253.03                5.55    46    78,669.39   5.85     0.95   0.63--1.44   0.806
  Gender                                                                                                                                
  Female                           101                  34,524.82                29.25   62    34,457.93   17.99    1.63   1.19--2.23   0.003
  Male                             66                   44,295.73                14.90   90    43,766.76   20.56    0.72   0.53--1.00   0.047
  Age                                                                                                                                   
  18--65 years                     58                   42,933.20                13.51   64    42,372.27   15.10    0.89   0.63--1.28   0.538
  \>65 years                       109                  35,887.35                30.37   88    35,852.42   24.55    1.24   0.93--1.64   0.137
  Hypertension                                                                                                                          
  No                               43                   28,179.04                15.26   48    27,305.24   17.58    0.87   0.58--1.31   0.500
  Yes                              124                  50,641.50                24.49   104   50,919.45   20.42    1.20   0.92--1.56   0.173
  Diabetes mellitus                                                                                                                     
  No                               105                  54,228.76                19.36   104   51,999.40   20.00    0.97   0.74--1.27   0.815
  Yes                              62                   24,591.79                25.21   48    26,225.29   18.30    1.38   0.95--2.01   0.096
  Dyslipidemia                                                                                                                          
  No                               93                   49,459.34                18.80   103   51,513.41   19.99    0.94   0.71--1.24   0.668
  Yes                              74                   29,361.21                25.20   49    26,711.28   18.34    1.37   0.96--1.97   0.085
  Gout                                                                                                                                  
  No                               118                  57,675.98                20.46   115   60,791.02   18.92    1.08   0.84--1.40   0.550
  Yes                              49                   21,144.57                23.17   37    17,433.67   21.22    1.09   0.71--1.67   0.686
  Systemic lupus erythematosus                                                                                                          
  No                               163                  77,577.48                21.01   150   77,867.36   19.26    1.09   0.87--1.36   0.443
  Yes                              4                    1243.06                  32.18   2     357.33      55.97    0.57   0.11--3.14   0.523
  Atrial fibrillation                                                                                                                   
  No                               154                  74,240.54                20.74   139   73,796.08   18.84    1.10   0.88--1.39   0.410
  Yes                              13                   4580.01                  28.38   13    4428.61     29.35    0.97   0.45--2.09   0.932
  Chronic ischemic heart disease                                                                                                        
  No                               85                   52,647.86                16.15   96    53,130.35   18.07    0.89   0.67--1.20   0.450
  Yes                              82                   26,172.68                31.33   56    25,094.34   22.32    1.40   1.00--1.97   0.050
  Peripheral vascular disease                                                                                                           
  No                               140                  71,858.15                19.48   132   71,302.58   18.51    1.05   0.83--1.33   0.674
  Yes                              27                   6962.40                  38.78   20    6922.11     28.89    1.34   0.75--2.39   0.319
  Chronic kidney disease                                                                                                                
  No                               146                  70,479.76                20.72   133   70,274.14   18.93    1.09   0.87--1.38   0.451
  Yes                              21                   8340.79                  25.18   19    7950.55     23.90    1.05   0.57--1.96   0.869
  Obesity                                                                                                                               
  No                               166                  78,215.13                21.22   150   77,406.90   19.38    1.10   0.88--1.37   0.419
  Yes                              1                    605.42                   16.52   2     817.79      24.46    0.68   0.06--7.45   0.749
  Exposure to NSAID                                                                                                                     
  \<1 month                        30                   6941.74                  43.22   39    10,403.76   37.49    1.15   0.72--1.86   0.558
  1--6 months                      47                   24,723.47                19.01   50    25,783.44   19.39    0.98   0.66--1.46   0.922
  \>6 months                       90                   47,155.33                19.09   63    42,037.49   14.99    1.27   0.92--1.76   0.141
  Exposure to steroid                                                                                                                   
  \<1 month                        99                   46,136.23                21.46   105   51,630.36   20.34    1.06   0.80--1.39   0.702
  1--6 months                      45                   21,297.60                21.13   32    18,851.76   16.97    1.24   0.79--1.96   0.344
  \>6 months                       23                   11,386.72                20.20   15    7742.57     19.37    1.04   0.54--2.00   0.900
  Follow-up period after surgery                                                                                                        
  \<30 days                        9                    999.91                   90.01   12    1000.38     119.95   0.75   0.32--1.78   0.515
  31--365 days                     34                   10,464.17                32.49   34    10,380.73   32.75    0.99   0.62--1.60   0.974
  1--3 years                       38                   19,209.97                19.78   31    18,864.33   16.43    1.20   0.75--1.93   0.444
  3--5 years                       32                   15,023.24                21.30   22    14,751.51   14.91    1.43   0.83--2.46   0.198
  \>5 years                        54                   33,123.25                16.30   53    33,227.75   15.95    1.02   0.70--1.49   0.910

\* Rate denotes incidence rate (per 10,000 person-years). Abbreviations: VTE---venous thromboembolic event; DVT---deep venous thrombosis; PE---pulmonary embolism; ONFH---osteonecrosis of femoral head; PY---person-years; IRR---incidence rate ratio; CI---confidence interval; NSAID---non-steroid anti-inflammatory drug.
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###### 

Multivariate \* Cox regression analysis for identifying the predictors of VTE, including DVT and PE, after hip replacement surgery.

                                   VTE    DVT          PE                                                          
  -------------------------------- ------ ------------ --------- ------ ------------ --------- ------ ------------ -------
  ONFH                             1.14   0.91--1.42   0.262     1.22   0.94--1.56   0.130     0.95   0.62--1.44   0.802
  Gender (ref.: female)                                                                                            
  Male                             0.84   0.66--1.07   0.152     0.92   0.69--1.21   0.530     0.68   0.43--1.09   0.106
  Age (ref.: 18--65 years)                                                                                         
  \>65 years                       1.62   1.24--2.11   \<0.001   1.55   1.15--2.10   0.004     1.72   1.04--2.84   0.035
  Comorbidities                                                                                                    
  Hypertension                     1.09   0.82--1.45   0.540     1.11   0.81--1.53   0.507     1.01   0.59--1.73   0.978
  Diabetes mellitus                0.97   0.76--1.24   0.796     1.06   0.80--1.41   0.678     0.73   0.45--1.17   0.185
  Dyslipidemia                     1.05   0.81--1.35   0.732     0.94   0.70--1.25   0.649     1.58   0.99--2.51   0.053
  Gout                             1.23   0.94--1.60   0.133     1.26   0.93--1.70   0.130     1.05   0.63--1.75   0.861
  Systemic lupus erythematosus     2.00   0.87--4.58   0.104     1.83   0.67--5.05   0.242     1.99   0.47--8.48   0.354
  Atrial fibrillation              1.12   0.74--1.70   0.580     1.08   0.67--1.75   0.748     1.34   0.66-2.73    0.419
  Chronic ischemic heart disease   1.36   1.05--1.74   0.018     1.23   0.92--1.65   0.155     1.71   1.07--2.73   0.025
  Peripheral vascular disease      1.57   1.14--2.17   0.006     1.96   1.39--2.78   \<.001    0.90   0.44--1.82   0.763
  Chronic kidney disease           0.96   0.68--1.35   0.810     1.04   0.71--1.52   0.859     0.65   0.31--1.37   0.254
  Obesity                          1.06   0.34--3.32   0.924     0.46   0.06--3.29   0.439     2.36   0.57--9.76   0.236
  Drug exposure                                                                                                    
  NSAID (ref.: \<1 month)                                                                                          
  1--6 months                      0.48   0.35--0.66   \<0.001   0.50   0.35--0.71   \<0.001   0.51   0.28--0.92   0.027
  \>6 months                       0.37   0.27--0.51   \<0.001   0.37   0.26--0.53   \<0.001   0.34   0.18--0.63   0.001
  Steroid (ref.: \<1 month)                                                                                        
  1--6 months                      1.05   0.80--1.39   0.719     0.97   0.70--1.34   0.859     1.38   0.82--2.32   0.231
  \>6 months                       1.03   0.71--1.49   0.886     0.86   0.56--1.35   0.520     1.83   0.97--3.43   0.062

\* Multivariate analysis was adjusted for age, gender, level of urbanization/income, comorbidities, and drugs. Abbreviations: VTE---venous thromboembolic event; DVT---deep venous thrombosis; PE---pulmonary embolism; ref.---reference; aHR---adjusted hazard ratio; CI---confidence interval; ONFH---osteonecrosis of femoral head; NSAID---non-steroid anti-inflammatory drug.
